Jahn Nora, Sack Ulrich, Stehr Sebastian, Vöelker Maria Theresa, Laudi Sven, Seehofer Daniel, Atay Selim, Zgoura Panagiota, Viebahn Richard, Boldt Andreas, Hau Hans-Michael
Department of Anesthesiology and Intensive Care Medicine, University Hospital of Leipzig, 04103 Leipzig, Germany.
Institute of Clinical Immunology, Medical Faculty, University of Leipzig, 04103 Leipzig, Germany.
J Clin Med. 2022 Oct 18;11(20):6148. doi: 10.3390/jcm11206148.
Background: Despite recent advances and refinements in perioperative management of kidney transplantation (KT), early renal graft injury (eRGI) remains a critical problem with serious impairment of graft function as well as short- and long-term outcome. Serial monitoring of peripheral blood innate immune cells might be a useful tool in predicting post-transplant eRGI and graft outcome after KT. Methods: In this prospective study, medical data of 50 consecutive patients undergoing KT at the University Hospital of Leipzig were analyzed starting at the day of KT until day 10 after the transplantation. The main outcome parameter was the occurrence of eRGI and other outcome parameters associated with graft function/outcome. eRGI was defined as graft-related complications and clinical signs of renal IRI (ischemia reperfusion injury), such as acute tubular necrosis (ATN), delayed graft function (DGF), initial nonfunction (INF) and graft rejection within 3 months following KT. Typical innate immune cells including neutrophils, natural killer (NK) cells, monocytes, basophils and dendritic cells (myeloid, plasmacytoid) were measured in all patients in peripheral blood at day 0, 1, 3, 7 and 10 after the transplantation. Receiver operating characteristics (ROC) curves were performed to assess their predictive value for eRGI. Cutoff levels were calculated with the Youden index. Significant diagnostic immunological cutoffs and other prognostic clinical factors were tested in a multivariate logistic regression model. Results: Of the 50 included patients, 23 patients developed eRGI. Mean levels of neutrophils and monocytes were significantly higher on most days in the eRGI group compared to the non-eRGI group after transplantation, whereas a significant decrease in NK cell count, basophil levels and DC counts could be found between baseline and postoperative course. ROC analysis indicated that monocytes levels on POD 7 (AUC: 0.91) and NK cell levels on POD 7 (AUC: 0.92) were highly predictive for eRGI after KT. Multivariable analysis identified recipient age (OR 1.53 (95% CI: 1.003−2.350), p = 0.040), recipient body mass index > 25 kg/m2 (OR 5.6 (95% CI: 1.36−23.9), p = 0.015), recipient cardiovascular disease (OR 8.17 (95% CI: 1.28−52.16), p = 0.026), donor age (OR 1.068 (95% CI: 1.011−1.128), p = 0.027), <0.010), deceased-donor transplantation (OR 2.18 (95% CI: 1.091−4.112), p = 0.027) and cold ischemia time (CIT) of the renal graft (OR 1.005 (95% CI: 1.001−1.01), p = 0.019) as clinically relevant prognostic factors associated with increased eRGI following KT. Further, neutrophils > 9.4 × 103/μL on POD 7 (OR 16.1 (95% CI: 1.31−195.6), p = 0.031), monocytes > 1150 cells/ul on POD 7 (OR 7.81 (95% CI: 1.97−63.18), p = 0.048), NK cells < 125 cells/μL on POD 3 (OR 6.97 (95% CI: 3.81−12.7), p < 0.01), basophils < 18.1 cells/μL on POD 10 (OR 3.45 (95% CI: 1.37−12.3), p = 0.02) and mDC < 4.7 cells/μL on POD 7 (OR 11.68 (95% CI: 1.85−73.4), p < 0.01) were revealed as independent biochemical predictive variables for eRGI after KT. Conclusions: We show that the combined measurement of immunological innate variables (NK cells and monocytes on POD 7) and specific clinical factors such as prolonged CIT, increased donor and recipient age and morbidity together with deceased-donor transplantation were significant and specific predictors of eRGI following KT. We suggest that intensified monitoring of these parameters might be a helpful clinical tool in identifying patients at a higher risk of postoperative complication after KT and may therefore help to detect and—by diligent clinical management—even prevent deteriorated outcome due to IRI and eRGI after KT.
尽管肾移植(KT)围手术期管理最近取得了进展和改进,但早期肾移植损伤(eRGI)仍然是一个关键问题,严重损害移植肾功能以及短期和长期预后。连续监测外周血固有免疫细胞可能是预测KT术后eRGI和移植结果的有用工具。方法:在这项前瞻性研究中,分析了莱比锡大学医院连续50例接受KT患者从KT当天到移植后第10天的医疗数据。主要结局参数是eRGI的发生以及与移植功能/结局相关的其他结局参数。eRGI定义为与移植相关的并发症和肾IRI(缺血再灌注损伤)的临床体征,如急性肾小管坏死(ATN)、移植肾功能延迟恢复(DGF)、原发性无功能(INF)以及KT后3个月内的移植排斥反应。在移植后第0、1、3、7和10天对所有患者外周血中的典型固有免疫细胞进行检测,包括中性粒细胞、自然杀伤(NK)细胞、单核细胞、嗜碱性粒细胞和树突状细胞(髓样、浆细胞样)。绘制受试者工作特征(ROC)曲线以评估其对eRGI的预测价值。使用约登指数计算临界值。在多变量逻辑回归模型中测试显著的诊断性免疫临界值和其他预后临床因素。结果:在纳入的50例患者中,23例发生了eRGI。与非eRGI组相比,移植后大多数日子里,eRGI组中性粒细胞和单核细胞的平均水平显著更高,而在基线和术后过程中,NK细胞计数、嗜碱性粒细胞水平和树突状细胞计数显著下降。ROC分析表明,术后第7天单核细胞水平(AUC:0.91)和术后第7天NK细胞水平(AUC:0.92)对KT后eRGI具有高度预测性。多变量分析确定受者年龄(OR 1.53(95%CI:1.003 - 2.350),p = 0.040)、受者体重指数>25 kg/m²(OR 5.6(95%CI:1.36 - 23.9),p = 0.015)、受者心血管疾病(OR 8.17(95%CI:1.28 - 52.16),p = 0.026)、供者年龄(OR 1.068(95%CI:1.011 - 1.128),p = 0.027)、<0.010)、脑死亡供者移植(OR 2.18(95%CI:1.091 - 4.112)),p = 0.027)和肾移植冷缺血时间(CIT)(OR 1.005(95%CI:1.001 - 1.01),p = 0.019)为与KT后eRGI增加相关的临床相关预后因素。此外,术后第7天中性粒细胞>9.4×10³/μL(OR 16.1(95%CI:1.31 - 195.6),p = 0.031)、术后第7天单核细胞>1150细胞/μL(OR 7.81(95%CI:1.97 - 63.18),p = 0.048)、术后第3天NK细胞<125细胞/μL(OR 6.97(95%CI:3.81 - 12.7),p<0.01)、术后第10天嗜碱性粒细胞<18.1细胞/μL(OR 3.45(95%CI:1.37 - 12.3),p = 0.02)和术后第7天髓样树突状细胞<4.7细胞/μL(OR 11.68(95%CI:1.85 - 73.4),p<0.01)被揭示为KT后eRGI的独立生化预测变量。结论:我们表明,免疫固有变量(术后第7天的NK细胞和单核细胞)与特定临床因素(如延长的CIT、供者和受者年龄增加以及发病率)以及脑死亡供者移植的联合测量是KT后eRGI的显著和特异性预测指标。我们建议加强对这些参数的监测可能是一种有用的临床工具,用于识别KT术后并发症风险较高的患者,因此可能有助于检测并通过积极的临床管理甚至预防KT后因IRI和eRGI导致的预后恶化。